



April 4, 2019

You are cordially invited to attend the 2019 Annual Meeting of Stockholders of Natera, Inc. that will be held on Thursday, May 16, 2019 at 11:30 a.m. Pacific Time, at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP located at 550 Allerton Street, Redwood City, CA 94063.

Details regarding admission to the Annual Meeting and the business to be conducted are described in the accompanying proxy materials. Also included is a copy of our 2018 Annual Report. We encourage you to read this information carefully.

Your vote is important. Whether or not you plan to attend the Annual Meeting, we hope you will vote as soon as possible. You may vote over the Internet, by telephone or by mailing a proxy card, if you have requested one. Voting over the Internet, by telephone or by written proxy will ensure your representation at the Annual Meeting regardless of whether or not you attend in person. Please review the instructions on the Notice of Internet Availability of Proxy Materials you received in the mail regarding each of these voting options.

Thank you for your ongoing support of Natera.

Very truly yours,

Steve Chapman  
*Chief Executive Officer and President*

**NATERA, INC.**  
**201 Industrial Road, Suite 410**  
**San Carlos, California 94070**

**NOTICE OF ANNUAL MEETING**  
**FOR 2019 ANNUAL MEETING OF STOCKHOLDERS**

---

- Time and Date:** . . . . . Thursday, May 16, 2019 at 11:30 a.m. Pacific Time.
- Place:** . . . . . Offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP located at 550 Allerton Street, Redwood City, CA 94063.
- Items of Business:** . . . . .
- (1) To elect the three directors named in the proxy statement accompanying this notice to serve as Class I directors until the annual meeting held in 2022 and until their successors are duly elected and qualified.
  - (2) To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2019.
  - (3) To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
- These items of business are more fully described in the proxy statement accompanying this notice.
- Adjournments and Postponements:** . . Any action on the items of business described above may be considered at the Annual Meeting at the time and on the date specified above or at any time and date to which the Annual Meeting may be properly adjourned or postponed.
- Record Date:** . . . . . You are entitled to vote if you were a stockholder of record as of the close of business on March 26, 2019.
- Voting:** . . . . . Your vote is very important. Whether or not you plan to attend the Annual Meeting, we encourage you to read the proxy statement and vote on the Internet or by telephone or submit your proxy card, if you have requested one, as soon as possible. For specific instructions on how to vote your shares, please refer to the section entitled "Questions and Answers About Procedural Matters."

A Notice of Internet Availability of Proxy Materials (Notice) will be mailed to stockholders of record on or about April 5, 2019. The Notice contains instructions on how to access our proxy statement for our 2019 Annual Meeting of Stockholders and our 2018 Annual Report to Stockholders on Form 10-K (together, the proxy materials). The Notice also provides instructions on how to vote online, by telephone or by mail and includes instructions on how to receive a paper copy of proxy materials by mail. The proxy materials can be accessed directly at the following Internet address: [www.edocumentview.com/NTRA](http://www.edocumentview.com/NTRA).

If you have any questions regarding this information or the proxy materials, please visit our website at [www.natera.com](http://www.natera.com) or contact our investor relations department at 650-249-9090.

All stockholders are cordially invited to attend the Annual Meeting in person.

By order of the board of directors,

A handwritten signature in black ink, appearing to read 'Steve Chapman', with a long horizontal flourish extending to the right.

Steve Chapman  
*Chief Executive Officer and President*

*This notice of annual meeting, proxy statement and accompanying form of proxy card are being made available on or about April 4, 2019.*

## TABLE OF CONTENTS

	<u>Page</u>
QUESTIONS AND ANSWERS ABOUT PROCEDURAL MATTERS .....	1
Annual Meeting .....	1
Stock Ownership .....	2
Quorum and Voting .....	2
Stockholder Proposals and Director Nominations .....	6
Additional Information about the Proxy Materials .....	7
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON MAY 16, 2019 .....	8
PROPOSAL ONE—ELECTION OF DIRECTORS .....	9
General .....	9
Nominees .....	9
Information Regarding the Nominees and Other Directors .....	9
PROPOSAL TWO—RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM .....	13
General .....	13
Principal Accounting Fees and Services .....	13
Pre-Approval of Audit and Non-Audit Services .....	13
CORPORATE GOVERNANCE .....	15
Code of Conduct .....	15
Board Composition .....	15
Director Independence .....	15
Board Leadership Structure .....	16
Board Committees .....	16
Stockholder Recommendations for Nominations to the Board of Directors .....	18
Compensation Committee Interlocks and Insider Participation .....	19
Meetings of the Board of Directors .....	19
Board Oversight of Risk .....	19
Director Compensation .....	19
Stockholder Communications with the Board of Directors .....	22
EXECUTIVE OFFICERS .....	23
EXECUTIVE COMPENSATION .....	24
Summary Compensation Table .....	24
Narrative Explanation of Compensation Arrangements with Our Named Executive Officers ...	25
Outstanding Equity Awards at 2018 Fiscal Year-End .....	27
Severance and Change in Control Benefits .....	29
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ..	31
EQUITY COMPENSATION PLAN INFORMATION .....	34
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS .....	35
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE .....	36
AUDIT COMMITTEE REPORT .....	37
OTHER MATTERS .....	38

**NATERA, INC.**  
**201 Industrial Road, Suite 410**  
**San Carlos, California 94070**

**PROXY STATEMENT FOR 2019 ANNUAL MEETING OF STOCKHOLDERS**

---

This proxy statement is furnished in connection with solicitation of proxies by our board of directors for use at the 2019 annual meeting of stockholders (the Annual Meeting) to be held at 11:30 a.m. Pacific Time on Thursday, May 16, 2019, and any postponements or adjournments thereof. The Annual Meeting will be held at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP located at 550 Allerton Street, Redwood City, CA 94063. Beginning on or about April 5, 2019, we will mail to our stockholders a Notice of Internet Availability of Proxy Materials (the Notice) containing instructions on how to access our proxy materials. As used in this proxy statement, the terms “Natera,” the “Company,” “we,” “us,” and “our” mean Natera, Inc. and its subsidiaries unless the context indicates otherwise.

**QUESTIONS AND ANSWERS ABOUT PROCEDURAL MATTERS**

**Annual Meeting**

**Q: Why am I receiving these proxy materials?**

A: You are receiving these proxy materials from us because you were a stockholder of record at the close of business on March 26, 2019 (the Record Date). Our board of directors is providing these proxy materials to you in connection with the solicitation of proxies for use at the Annual Meeting to be held on Thursday, May 16, 2019 at 11:30 a.m. Pacific Time, and at any adjournment or postponement thereof, for the purpose of considering and acting upon the matters set forth herein. The notice of Annual Meeting, this proxy statement and accompanying form of proxy card are being made available to you on or about April 4, 2019. This proxy statement includes information that we are required to provide to you under SEC rules and that is designed to assist you in voting your shares.

**Q: What is included in the proxy materials?**

A: The proxy materials include:

- this proxy statement for the Annual Meeting;
- our 2018 Annual Report to Stockholders, which consists of our Annual Report on Form 10-K for the year ended December 31, 2018; and
- the proxy card or a voting instruction form for the Annual Meeting, if you have requested that the proxy materials be mailed to you.

**Q: How can I get electronic access to the proxy materials?**

A: Our proxy materials are available at [www.edocumentview.com/NTRA](http://www.edocumentview.com/NTRA) and at <http://investor.natera.com>. Our website address is included for reference only. The information contained on our website is not incorporated by reference into this proxy statement.

You can find directions on how to instruct us to send future proxy materials to you by email at [www.edocumentview.com/NTRA](http://www.edocumentview.com/NTRA). Choosing to receive future proxy materials by email will save us the cost of printing and mailing documents to you and will reduce the impact of our annual meetings on the environment. If you choose to receive future proxy materials by email, you will receive an email message next year with instructions containing a link to those materials and a link to the proxy voting website. Your election to receive proxy materials by email will remain in effect until you terminate it.

**Q: What information is contained in this proxy statement?**

A: The information in this proxy statement relates to the proposals to be voted on at the Annual Meeting, the voting process, the compensation of our directors and certain of our executive officers, corporate governance, and certain other required information.

**Q: Where is the Annual Meeting?**

A: The Annual Meeting will be held at the offices of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP located at 550 Allerton Street, Redwood City, CA 94063. Directions to this location are available at [www.gunder.com/contact](http://www.gunder.com/contact). The telephone number at our principal executive offices is (650) 249-9090.

**Q: Can I attend the Annual Meeting?**

A: You are invited to attend the Annual Meeting if you were a stockholder of record or a beneficial owner as of March 26, 2019. Admission will begin at 11:00 a.m. Pacific Time on the date of the Annual Meeting, and you must present valid picture identification such as a driver's license or passport and, if asked, provide proof of stock ownership as of March 26, 2019. The use of mobile phones, pagers, recording or photographic equipment, tablets and/or computers is not permitted at the Annual Meeting. The meeting will begin promptly at 11:30 a.m. Pacific Time.

**Stock Ownership**

**Q: What is the difference between holding shares as a stockholder of record and as a beneficial owner?**

A: *Stockholders of record*—If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., you are considered, with respect to those shares, the “stockholder of record,” and the Notice was provided to you directly by us. As the stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or to vote in person at the Annual Meeting.

*Beneficial owners*—Many Natera stockholders hold their shares through a broker, trustee or other nominee, rather than directly in their own name. If your shares are held in a brokerage account or by a bank or another nominee, you are considered the “beneficial owner” of shares held in “street name.” The Notice was forwarded to you by your broker, trustee or nominee who is considered, with respect to those shares, the stockholder of record.

As the beneficial owner, you have the right to direct your broker, trustee or nominee on how to vote your shares. Beneficial owners are also invited to attend the Annual Meeting. However, since beneficial owners are not stockholders of record, you may not vote your shares in person at the Annual Meeting unless you follow your broker's procedures for obtaining a legal proxy. If you request a printed copy of the proxy materials by mail, your broker or nominee will provide a voting instruction card for you to use.

**Quorum and Voting**

**Q: How many shares must be present or represented to conduct business at the Annual Meeting?**

A: A quorum is the minimum number of shares required to be present at the Annual Meeting for the meeting to be properly held under our amended and restated bylaws, or bylaws, and Delaware state law. The presence, in person or by proxy, of a majority of the aggregate voting power of the issued and outstanding shares of stock entitled to vote at the meeting will constitute a quorum at the meeting. Except as otherwise expressly provided by our amended and restated certificate of

incorporation, or certificate of incorporation, or by law, the holders of shares of common stock will vote together as a single class on all matters submitted to a vote or for the consent of the stockholders of Natera. Each holder of common stock will have the right to one vote per share of common stock. A proxy submitted by a stockholder may indicate that the shares represented by the proxy are not being voted (“withhold,” or “abstain”) with respect to a particular matter.

Under the General Corporation Law of the State of Delaware and our bylaws, abstentions and broker “non-votes” are counted as present and entitled to vote and are, therefore, included for purposes of determining whether a quorum is present at the Annual Meeting.

A broker non-vote occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item and has not received instructions from the beneficial owner.

**Q: Who is entitled to vote at the Annual Meeting?**

A: Holders of record of our common stock at the close of business on March 26, 2019 (the Record Date) are entitled to receive notice of and to vote their shares at the Annual Meeting. As of the Record Date, we had 63,127,816 shares of common stock outstanding. In deciding all matters at the Annual Meeting, each holder of common stock of Natera will be entitled to one vote for each share of common stock held as of the close of business on the Record Date. We do not have cumulative voting rights for the election of directors.

**Q: How can I vote my shares in person at the Annual Meeting?**

A: Shares held in your name as the stockholder of record may be voted in person at the Annual Meeting. Shares held beneficially in street name may be voted in person at the Annual Meeting only if you obtain a legal proxy from the broker, trustee or other nominee that holds your shares giving you the right to vote the shares. **Even if you plan to attend the Annual Meeting, we recommend that you also submit your proxy card, if you have requested one, or following the voting directions described below, so that your vote will be counted if you later decide not to attend the meeting.**

**Q: How can I vote my shares without attending the Annual Meeting?**

A: *Stockholder of record*—If you are a stockholder of record, there are three ways to vote without attending the Annual Meeting:

- *Via the Internet*—You may vote by proxy via the Internet by following the instructions provided in the Notice or, if you requested printed copies of the proxy materials by mail, by following the instructions provided in the proxy card.
- *By Telephone*—You may vote by proxy by telephone by following the instructions provided in the Notice or, if you requested printed copies of the proxy materials by mail, by calling the toll free number found on the proxy card.
- *By Mail*—If you request printed copies of the proxy materials by mail, you will receive a proxy card and you may vote by proxy by filling out the proxy card and returning it in the envelope provided.

*Beneficial owners*—If you are a beneficial owner holding shares through a bank, broker or other nominee, please refer to your Notice or other information forwarded by your bank or broker to see which voting options are available to you.

**Q: What proposals will be voted on at the Annual Meeting?**

A: At the Annual Meeting, stockholders will be asked to vote:

- (1) to elect the three directors identified in this proxy statement to serve as Class I directors until the annual meeting held in 2022 and until their successors are duly elected and qualified;
- (2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019, and
- (3) to transact such other business as may properly come before the Annual Meeting or any adjournment thereof.

**Q: What is the voting requirement to approve each of the proposals?**

A: *Proposal One*—The election of directors requires a plurality vote of the shares of common stock voted at the meeting. “Plurality” means that the individuals who receive the largest number of votes cast “for” are elected as directors. As a result, any shares not voted “for” a particular nominee (whether as a result of withholding, abstention or a broker non-vote) will not be counted in such nominee’s favor.

*Proposal Two*—The affirmative vote of a majority of votes cast is required to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm. Abstentions and broker non-votes will have no effect on the outcome of this proposal.

**Q: How does the board of directors recommend that I vote?**

A: Our board of directors unanimously recommends that you vote your shares:

- “FOR” the three nominees for election as director listed in Proposal One; and
- “FOR” the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019.

**Q: What happens if I do not give specific voting instructions?**

A: *Stockholder of record*—If you are a stockholder of record and you:

- indicate when voting on the Internet or by telephone that you wish to vote as recommended by our board of directors; or
- sign and return a proxy card without giving specific voting instructions,

then the persons named as proxy holders will vote your shares in the manner recommended by the Board on all matters presented in this proxy statement and as the proxy holders may determine in their discretion with respect to any other matters properly presented for a vote at the Annual Meeting.

If you are a stockholder of record and you do not return a proxy card and do not vote your shares, no votes will be cast on your behalf on any of the items of business at the Annual Meeting.



*Beneficial owners*—If you are a beneficial owner of shares held in street name and do not provide the organization that holds your shares with specific voting instructions then, under applicable rules, the organization that holds your shares may generally vote on “routine” matters but cannot vote on “non-routine” matters. If the organization that holds your shares does not receive instructions from you on how to vote your shares on a non-routine matter, that organization will inform the inspector of election that it does not have the authority to vote on this matter with respect to your shares. This is generally referred to as a “broker non-vote.”

**Q: How may my brokerage firm or other intermediary vote my shares if I fail to provide timely directions?**

A: Brokerage firms and other intermediaries holding shares of common stock in street name for customers are generally required to vote such shares in the manner directed by their customers. In the absence of timely directions, your broker will have discretion to vote your shares on our sole routine matter—the proposal to ratify the appointment of Ernst & Young LLP. Your broker will not have discretion to vote on the following “non-routine” matter absent direction from you: the election of directors.

**Please note that brokers may not vote your shares on the election of directors in the absence of your specific instructions as to how to vote, so we encourage you to provide instructions to your broker regarding the voting of your shares.**

**Q: What happens if additional matters are presented at the Annual Meeting?**

A: If any other matters are properly presented for consideration at the Annual Meeting, including, among other things, consideration of a motion to adjourn the Annual Meeting to another time or place (including, without limitation, for the purpose of soliciting additional proxies), the persons named in the proxy card and acting thereunder will have discretion to vote on those matters in accordance with their best judgment. We do not currently anticipate that any other matters will be raised at the Annual Meeting.

**Q: Can I change or revoke my vote?**

A: Subject to any rules your broker, trustee or nominee may have, you may change your proxy instructions at any time before your proxy is voted at the Annual Meeting.

If you are a stockholder of record, you may change your vote by (i) filing with our Corporate Secretary, prior to your shares being voted at the Annual Meeting, a written notice of revocation or a duly executed proxy card, in either case dated later than the prior proxy card relating to the same shares, or (ii) by attending the Annual Meeting and voting in person (although attendance at the Annual Meeting will not, by itself, revoke a proxy). A stockholder of record that has voted on the Internet or by telephone may also change his or her vote by later making a timely and valid Internet or telephone vote.

If you are a beneficial owner of shares held in street name, you may change your vote (i) by submitting new voting instructions to your broker, trustee or other nominee or (ii) if you have obtained a legal proxy from the broker, trustee or other nominee that holds your shares giving you the right to vote the shares, by attending the Annual Meeting and voting in person.

Any written notice of revocation or subsequent proxy card must be received by our Corporate Secretary prior to the taking of the vote at the Annual Meeting. Such written notice of revocation or subsequent proxy card should be hand delivered to our Corporate Secretary or should be sent so as to be delivered to our principal executive offices, Attention: Corporate Secretary.

**Q: Who will bear the cost of soliciting votes for the Annual Meeting?**

A: We will bear all expenses of this solicitation, including the cost of preparing and mailing these proxy materials. We may reimburse brokerage firms, custodians, nominees, fiduciaries and other persons representing beneficial owners of common stock for their reasonable expenses in forwarding solicitation material to such beneficial owners. Directors, officers and employees of Natera may also solicit proxies in person or by other means of communication. Such directors, officers and employees will not be additionally compensated but may be reimbursed for reasonable out-of-pocket expenses in connection with such solicitation. We may engage the services of a professional proxy solicitation firm to aid in the solicitation of proxies from certain brokers, bank nominees and other institutional owners. Our costs for such services, if retained, will not be significant.

**Q: Is my vote confidential?**

A: Proxy instructions, ballots, and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within Natera or to third parties, except as necessary to meet applicable legal requirements, to allow for the tabulation of votes and certification of the vote, or to facilitate a successful proxy solicitation.

**Q: Who will serve as inspector of elections?**

A: The inspector of elections will be a representative from Computershare Trust Company, N.A.

**Q: Where can I find the voting results of the Annual Meeting?**

A: We intend to announce preliminary voting results at the Annual Meeting and will publish final results in a current report on Form 8-K within four business days after the Annual Meeting.

**Stockholder Proposals and Director Nominations**

**Q: What is the deadline to propose actions for consideration at next year's annual meeting of stockholders or to nominate individuals to serve as directors?**

A: You may submit proposals, including director nominations, for consideration at future stockholder meetings.

*Requirements for stockholder proposals to be considered for inclusion in our proxy materials—*

Stockholders may present proper proposals for inclusion in our proxy statement and for consideration at our 2020 annual meeting of stockholders by submitting their proposals in writing to our Corporate Secretary in a timely manner. In order to be included in the proxy statement for the 2020 annual meeting of stockholders, stockholder proposals must be received by our Corporate Secretary no later than December 5, 2019, and must otherwise comply with the requirements of Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the Exchange Act).

*Requirements for stockholder proposals to be brought before an annual meeting—*In addition, our bylaws establish an advance notice procedure for stockholders who wish to present certain matters before an annual meeting of stockholders. In general, nominations for the election of directors may be made by our board of directors or any committee thereof or any stockholder, who (i) is a stockholder of record on the date of the giving of such notice and on the record date for the determination of stockholders entitled to vote at such meeting, (ii) is entitled to vote at such meeting, and (iii) has delivered written notice to our Corporate Secretary no later than the Notice Deadline (as defined below), which notice must contain specified information concerning the nominees and concerning the stockholder proposing such nominations.

Our bylaws also provide that the only business that may be conducted at an annual meeting is business that is (i) specified in the notice of meeting (or any supplement thereto) given by or at the direction of our board of directors, (ii) otherwise properly brought before the meeting by or at the direction of our board of directors (or any committee thereof) or (iii) properly brought before the meeting by a stockholder who has delivered written notice to our Corporate Secretary no later than the Notice Deadline (as defined below).

The “Notice Deadline” is defined as that date which is not less than 90 days nor more than 120 days prior to the one-year anniversary of the previous year’s annual meeting of stockholders. As a result, the Notice Deadline for the 2020 annual meeting of stockholders is between January 17, 2020 and February 16, 2020.

If a stockholder who has notified us of his or her intention to present a proposal at an annual meeting does not appear to present his or her proposal at such meeting, we need not present the proposal for vote at such meeting.

*Recommendation of director candidates*—You may recommend candidates to our board of directors for consideration by our nominating and corporate governance committee by following the procedures set forth below in “Corporate Governance—Stockholder Recommendations for Nominations to the Board of Directors.”

**Q: How may I obtain a copy of the bylaw provisions regarding stockholder proposals and director nominations?**

A: A copy of the full text of the bylaw provisions discussed above may be obtained by writing to our Corporate Secretary. A copy of our bylaws is posted on the Investor Relations section of our website at <http://investor.natera.com>. All notices of proposals by stockholders, whether or not included in Natera’s proxy materials, should be sent to our principal executive offices, Attention: Corporate Secretary.

**Additional Information about the Proxy Materials**

**Q: Why did I receive a notice regarding the availability of proxy materials on the Internet instead of a full set of proxy materials?**

A: In accordance with the rules of Securities and Exchange Commission (SEC), we have elected to furnish our proxy materials, including this proxy statement and our annual report to our stockholders, primarily via the Internet. Beginning on or about April 5, 2019, we will mail to our stockholders a “Notice of Internet Availability of Proxy Materials” that contains notice of the Annual Meeting and instructions on how to access our proxy materials on the Internet, how to vote at the meeting, and how to request printed copies of the proxy materials and annual report. Stockholders may request to receive all future proxy materials in printed form by mail or electronically by e-mail by following the instructions contained at [www.edocumentview.com/NTRA](http://www.edocumentview.com/NTRA). We encourage stockholders to take advantage of the availability of the proxy materials on the Internet to help reduce the environmental impact of our annual meetings.

**Q: What does it mean if multiple members of my household are stockholders but we only received one Notice or full set of proxy materials in the mail?**

A: We have adopted a procedure called “householding,” which the SEC has approved. Under this procedure, we deliver a single copy of the Notice and, if applicable, the proxy materials to multiple stockholders who share the same address unless we received contrary instructions from one or more of the stockholders. This procedure reduces our printing costs, mailing costs, fees, and impact on the environment. Stockholders who participate in householding will continue to be able

to access and receive separate proxy cards. Upon written request, we will deliver promptly a separate copy of the Notice and, if applicable, the proxy materials to any stockholder at a shared address to which we delivered a single copy of any of these documents. To receive a separate copy of the Notice and, if applicable, the proxy materials, stockholders should send their requests to our principal executive offices, Attention: Corporate Secretary. Stockholders who hold shares in street name (as described below) may contact their brokerage firm, bank, broker-dealer, or other similar organization to request information about householding.

**Q: What is the mailing address for Natera's principal executive offices?**

A: Our principal executive offices are located at 201 Industrial Road, Suite 410, San Carlos, California 94070. The telephone number at that location is (650) 249-9090.

Any written requests for additional information, copies of the proxy materials and 2018 Annual Report, notices of stockholder proposals, recommendations for candidates to our board of directors, communications to our board of directors or any other communications should be sent to the address above.

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON MAY 16, 2019.**

**The proxy statement and annual report to stockholders is available at [www.edocumentview.com/NTRA](http://www.edocumentview.com/NTRA).**

**PROPOSAL ONE**  
**ELECTION OF DIRECTORS**

**General**

Our board of directors may establish the authorized number of directors from time to time by resolution. The number of authorized directors is currently ten. Our board of directors is currently comprised of ten members who are divided into three classes with staggered three-year terms. A director serves in office until his or her respective successor is duly elected and qualified or until his or her earlier death or resignation. Our certificate of incorporation and bylaws that are in effect authorize only our board of directors to fill vacancies on our board of directors until the next annual meeting of stockholders. Any additional directorships resulting from an increase in the authorized number of directors would be distributed among the three classes so that, as nearly as possible, each class would consist of one-third of the authorized number of directors. Your proxy cannot be voted for a greater number of persons than the number of nominees named in this proxy statement.

**Nominees**

Three Class I directors have been nominated for election at the Annual Meeting, each for a three-year term expiring in 2022, or until such director's successor has been duly elected and qualified. Upon the recommendation of our nominating and corporate governance committee, our board of directors has nominated **Roy Baynes, James I. Healy** and **Gail Marcus** for election as Class I directors. Dr. Edward C. Driscoll, Jr.'s service as a director will end when his term expires at the Annual Meeting, and the number of authorized directors will be reduced to nine at that time.

**Information Regarding the Nominees and Other Directors**

*Nominees for Class I Directors For a Term Expiring in 2022*

*Roy Baynes*, 64, has served as a member of our board of directors since July 2018. Dr. Baynes has been the Senior Vice President, Head of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories, a biopharmaceutical company, since December 2013. Prior to Merck, Dr. Baynes served as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences Inc., a biotechnology company, from January 2012 to December 2013 and the Vice President Global Development and Therapeutic Area Head Hematology Oncology at Amgen Inc., a biopharmaceutical company, from 2002 to 2012. Dr. Baynes also has been a director of Atara Biotherapeutics, Inc., a biopharmaceutical company, since September 2018 and a director of Retrophin, Inc., a biopharmaceutical company, since July 2016. Dr. Baynes has an M.D. and a Ph.D. from the University of the Witwatersrand, Johannesburg, South Africa. Our board of directors believes that Dr. Baynes is qualified to serve as a director based on his extensive experience in the biopharmaceutical industry and experience on other public company boards.

*James I. Healy, M.D., Ph.D.*, 54, has served as a member of our board of directors since November 2014. Dr. Healy has been a general partner at Sofinnova Investments (formerly Sofinnova Ventures), a biotechnology investment firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research based pharmaceutical company, and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S, a clinical-stage biopharmaceutical company; Coherus BioSciences, Inc., a biologics platform company; Iterum Therapeutics PLC, a clinical-stage pharmaceutical company; Nucana plc, a clinical-stage biopharmaceutical company; ObsEva SA, a clinical-stage biopharmaceutical company; Y-mAbs, an oncology biologics development company; and one private company. Previously, Dr. Healy served as a board member of Amarin Corporation plc, a commercial-stage

biopharmaceutical company; Auris Medical Holding AG, a specialty pharmaceuticals company; Edge Therapeutics, Inc., a clinical-stage biotechnology company; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company; InterMune, Inc., a biotechnology company; Anthera Pharmaceuticals, Inc., a biopharmaceutical company; Durata Therapeutics, Inc., a pharmaceutical company; CoTherix, Inc., a biopharmaceutical company; Movetis NV, a pharmaceutical company; and several private companies. Dr. Healy holds a Bachelor of Arts in Molecular Biology and in Scandinavian Studies from the University of California at Berkeley, and an M.D. and Ph.D. in Immunology from Stanford University School of Medicine. Our board of directors believes that Dr. Healy is qualified to serve as a director due to his significant medical background, extensive experience investing and working in the life science industry, and his extensive service on the boards of directors of other public and private life sciences companies. Dr. Healy currently serves on our nominating and corporate governance committee and on our compensation committee.

*Gail Marcus*, 62, joined our board of directors in March 2017. Ms. Marcus has served at the Massachusetts College of Pharmacy and Health Sciences since April 2016 as Assistant Professor and Director of the Global Healthcare Management and Biomedical Informatics programs, and also serves as Department Chair, Pharmaceutical Business and Administrative Services. From 2015 to September 2017, Ms. Marcus served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International, a consulting company. From October 2012 to December 2015, Ms. Marcus served as chief executive officer and president of Calloway Laboratories, a provider of clinical toxicology laboratory services. Prior to that, Ms. Marcus held a variety of leadership roles with diagnostics, pharmacy benefit management and managed care companies. Ms. Marcus currently serves on the boards of directors of a private company and a non-profit organization, and sits on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests. Ms. Marcus holds a Bachelor of Art in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School of Engineering, an M.B.A. from the Wharton School of the University of Pennsylvania, and is pursuing a Doctorate of Health Administration from the Medical University of South Carolina. Our board of directors believes that Ms. Marcus is qualified to serve as a director based on her financial and managerial experience and service on other boards of directors. Ms. Marcus currently serves as the chair of our audit committee and also serves as the chair of our nominating and corporate governance committee.

#### ***Incumbent Class II Directors Whose Term Expires in 2020***

*Herm Rosenman*, 71, has served as a member of our board of directors since February 2017, and served as our Chief Financial Officer from February 2014 to January 2017. Prior to joining our company, he held the position of senior vice president—finance and chief financial officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of diagnostic and screening products using nucleic acid probes, from June 2001 to August 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, since 2013, and of Vivus, Inc., a biopharmaceutical company, since 2013. Mr. Rosenman also previously served on the board of directors of Medistem, Inc., a stem cell therapy company, ARYx Therapeutics Inc., a private drug discovery and development company, Infinity Pharmaceuticals, Inc., a drug discovery and development company, and a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. Our board of directors believes that Mr. Rosenman is qualified to serve as a director based on his experience as our chief financial officer and his experience in the biopharmaceutical industry. Mr. Rosenman serves as an observer on our Audit Committee.



*Jonathan Sheena*, 46, is a co-founder of our company and has served as a member of our board of directors and as our Chief Technology Officer since 2007. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. From June 1999 to December 2007, Mr. Sheena held various roles at PhoneSpots, including Vice President of Product Management and Chief Technology Officer. Mr. Sheena holds a Bachelor of Science in Electrical Engineering and Computer Science, and a Master of Engineering in Electrical Engineering and Computer Science, from the Massachusetts Institute of Technology. Our board of directors believes that Mr. Sheena is qualified to serve as a director based on his experience as our co-founder and Chief Technology Officer, his experience with entrepreneurial companies, and his particular familiarity with technology companies.

***Incumbent Class III Directors Whose Term Expires in 2021***

*Roelof F. Botha*, 45, has served as a member of our board of directors since 2007. Mr. Botha has been with Sequoia Capital, a venture capital firm, since 2003, and has been a managing member of Sequoia Capital Operations, LLC since 2007. From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., ultimately as the chief financial officer. Mr. Botha currently serves on the board of directors of Square, Inc., a provider of payments, financial and marketing services; MongoDB, Inc., a document-oriented database program developer; Eventbrite, Inc., an event management and ticketing platform; and a number of private companies. Mr. Botha holds a Bachelor of Science in Actuarial Science, Economics, and Statistics from the University of Cape Town and an M.B.A. from Stanford University. Our board of directors believes that Mr. Botha is qualified to serve as a director based on his financial and managerial experience, his service on other public and private company boards of directors and his familiarity with technology companies. Mr. Botha is our Lead Independent Director and currently serves on our audit committee and nominating and corporate governance committee.

*Steve Chapman*, 40, has served as a member of our board of directors and as our Chief Executive Officer since January 2019. Previously, Mr. Chapman served as our Chief Operating Officer from August 2017 to January 2019, and Chief Commercial Officer from March 2017 to August 2017. Mr. Chapman has been with our company since December 2010 and held positions including the Vice President of Sales and Vice President, Commercial Operations. Prior to joining our company, Mr. Chapman worked at Genzyme Genetics Corp., a biotechnology company, from 2003 to 2010. Mr. Chapman holds a Bachelor of Science in Microbiology, Immunology and Molecular Genetics from University of California, Los Angeles. Our board of directors believes that Mr. Chapman is qualified to serve as a director based on his experience in various roles at our company and his experience in the biotechnology field.

*Todd Cozzens*, 63, has served as a member of our board of directors since 2011. Since 2016, Mr. Cozzens has been the co-founder and a managing partner of Leerink Transformation Partners, a growth equity fund which invests in healthcare information technology and services companies. Prior to forming Leerink Transformation Partners, Mr. Cozzens co-led healthcare investing at Sequoia Capital, a venture capital firm, from 2012 to 2015. From 2010 to 2012, Mr. Cozzens served as chief executive officer of Optum Accountable Care Solutions, a business unit of Optum/UnitedHealth Group, where he first helped with its formation and launch, and thereafter led several business areas including strategy and M&A. From 2000 to 2010, Mr. Cozzens was the co-founder and served as chief executive officer of Picis Inc., a provider of electronic medical record software to hospitals, until it was acquired by the UnitedHealth Group in 2010 and subsequently became a division of Optum. Mr. Cozzens currently serves on the boards of directors of a number of private companies. Mr. Cozzens holds a Bachelor of Arts degree from Marquette University, and completed the Program for Management Development at Harvard University. Our board of directors believes that Mr. Cozzens is qualified to serve as a director based on his financial and managerial experience, his service on private company boards of directors

and his experience with healthcare technology and information systems. Mr. Cozzens currently serves as the chair of our compensation committee and also serves on our audit committee.

*Matthew Rabinowitz, Ph.D.*, 46, is a co-founder of our company and served as our Chief Executive Officer from 2005 to January 2019. Dr. Rabinowitz has also served as a member of our board of directors since 2005; he served as Chairman of our board of directors from May 2015 to January 2019, at which time he assumed the role of Executive Chairman. Prior to co-founding our company, Dr. Rabinowitz served from 2000 to 2003 as chief executive officer and from 2003 to 2007 as chief technology officer of Rosum Corporation, a location services technology company. Dr. Rabinowitz has multiple publications in signal processing, machine learning, bio-informatics, and high-throughput genetic testing. He received the Scott Helt Memorial Award from the Institute of Electrical and Electronics Engineers and received Technology Pioneer Awards from the World Economic Forum for founding Rosum Corporation and Natera. He currently serves on the board of directors of a private company. Dr. Rabinowitz holds a Bachelor of Science degree in Engineering and Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering, from Stanford University. Our board of directors believes that Dr. Rabinowitz is qualified to serve as a director based on his experience as our co-founder and Chief Executive Officer, his service on a private company board, and his experience in the technology industry.

There are no family relationships among any of our directors or executive officers. See “Corporate Governance” and “Corporate Governance—Director Compensation” below for additional information regarding our board of directors.

**OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE CLASS I NOMINEES NAMED ABOVE.**



**PROPOSAL TWO**  
**RATIFICATION OF THE APPOINTMENT OF**  
**INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

**General**

Our audit committee has appointed the firm of Ernst & Young LLP, independent registered public accountants, to audit our financial statements for the year ending December 31, 2018. Ernst & Young LLP has audited our financial statements since the year ended December 31, 2011.

Notwithstanding its selection and even if our stockholders ratify the selection, our audit committee, in its discretion, may appoint another independent registered public accounting firm at any time during the year if the audit committee believes that such a change would be in the best interests of the company and its stockholders.

At the Annual Meeting, the stockholders are being asked to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019. Our audit committee is submitting the selection of Ernst & Young LLP to our stockholders because we value our stockholders' views on our independent registered public accounting firm and as a matter of good corporate governance. Representatives of Ernst & Young LLP will be present at the Annual Meeting and they will have an opportunity to make statements and will be available to respond to appropriate questions from stockholders.

If this proposal does not receive the affirmative approval of a majority of the votes cast on the proposal, the audit committee would reconsider the appointment.

**Principal Accounting Fees and Services**

The following table sets forth all fees paid or accrued by us for professional audit services and other services rendered by Ernst & Young LLP during the years ended December 31, 2018 and 2017:

	<u>2018</u>	<u>2017</u>
Audit Fees <sup>(1)</sup> . . . . .	\$1,663,111	\$1,437,811
Audit-Related Fees . . . . .	—	—
Tax Fees <sup>(2)</sup> . . . . .	21,000	—
All Other Fees <sup>(3)</sup> . . . . .	4,000	1,995
<b>Total Fees . . . . .</b>	<u><u>\$1,688,111</u></u>	<u><u>\$1,439,806</u></u>

- (1) Audit Fees: This category represents fees for professional services provided in connection with the audit of our financial statements, review of our quarterly financial statements, and audit services provided in connection with other regulatory or statutory filings for which we have engaged Ernst & Young LLP.
- (2) Tax Fees: This category consists of tax compliance, tax planning, and tax advice, including foreign tax return preparation.
- (3) All Other Fees: This category consists of subscription fees for accounting standards and financial reporting content database.

**Pre-Approval of Audit and Non-Audit Services**

Consistent with requirements of the SEC and the Public Company Accounting Oversight Board regarding auditor independence, our audit committee is responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our audit committee, or the chair if such approval is needed between meetings of the

audit committee, generally pre-approves of all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services.

**OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2019.**

## CORPORATE GOVERNANCE

### Code of Conduct

Our board of directors has adopted a code of conduct that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer, and other executive and senior officers. The full text of our code of conduct is posted in the Investor Relations section of our website at <http://investor.natera.com>. We intend to disclose future amendments to, or waiver of, our code of conduct, at the same location on our website identified above.

### Board Composition

Our business affairs are managed under the direction of our board of directors, which is currently composed of ten members. Six of our directors—Messrs. Botha and Cozzens, Drs. Baynes, Driscoll and Healy, and Ms. Marcus—are independent within the meaning of the listing rules of the Nasdaq Global Select Market (Nasdaq). Dr. Driscoll's service as a director will end when his term expires at the Annual Meeting, and the number of authorized directors will be reduced to nine at that time. Our board of directors is divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election.

Directors in a particular class will be elected for a three-year term at the annual meeting of stockholders in the year in which their terms expire. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing to serve for the remainder of their respective three-year terms. Each director's term continues until the election and qualification of his or her successor or the earlier of his or her death, resignation or removal. The classification of our board of directors may have the effect of delaying or preventing changes in our control or management.

### Director Independence

Our common stock is listed on Nasdaq. The listing rules of this stock exchange generally require that a majority of the members of a listed company's board of directors be independent. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company's audit, compensation, and nominating and corporate governance committees be independent. Under Nasdaq rules, a director will only qualify as an "independent director" if, in the opinion of that company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Our board of directors has determined that, except for Mr. Rosenman, who served as our chief financial officer until January 31, 2017, none of our non-employee directors has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under Nasdaq rules. The independent members of our board of directors will hold separate regularly scheduled executive session meetings at which only independent directors are present.

Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or be an affiliated person of the listed company or any of its subsidiaries. Each member of our audit committee, Messrs. Botha and Cozzens and Ms. Marcus, qualifies as an independent director pursuant to Rule 10A-3.

## **Board Leadership Structure**

Pursuant to our Corporate Governance Guidelines, our board of directors may separate or combine the roles of the chairman of the board of directors and chief executive officer when and if it deems it advisable and in our best interests and in the best interests of our stockholders to do so. These roles are currently separated, as Dr. Rabinowitz currently serves as Executive Chairman of our board of directors, while Mr. Chapman serves as our Chief Executive Officer. The board of directors regularly evaluates its leadership structure to determine which structure best serves the interests of the company and our stockholders as the company evolves, and believes that separating the roles of the chairman of the board of directors and chief executive officer is the appropriate leadership structure for us at this time, as it allows our Chief Executive Officer to focus on our day-to-day business while allowing our Executive Chairman to continue to advise the company and its management, provide strategic guidance, and interface with our board of directors.

In addition, pursuant to our Corporate Governance Guidelines, if the chairman of our board of directors is not an independent director, the board of directors will appoint a Lead Independent Director to facilitate communication between management, the independent directors and the chairman of our board of directors, as well as participate in setting agendas for meetings and presiding at executive sessions of the board of directors. Although the roles of the chairman of the board of directors and chief executive officer are currently separated, because our executive chairman is not an independent director, our board of directors deems it in the best interest of the company and its stockholders to maintain the appointment of Mr. Botha as the Lead Independent Director.

Our Corporate Governance Guidelines are posted in the Investor Relations section of our website at <http://investor.natera.com>.

## **Board Committees**

Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Our board of directors and its committees set schedules for meeting throughout the year and can also hold special meetings and act by written consent from time to time, as appropriate. Our board of directors has delegated various responsibilities and authority to its committees as generally described below. The committees regularly report on their activities and actions to the full board of directors. Each member of each committee of our board of directors qualifies as an independent director in accordance with Nasdaq listing standards. Each committee of our board of directors has a written charter approved by our board of directors. Copies of each charter are posted in the Investor Relations section of our website at <http://investor.natera.com>.

### *Audit Committee*

Our audit committee was established in May 2015. During the year ended December 31, 2018, our audit committee held three meetings and met informally on other occasions. The members of our audit committee are currently comprised of Messrs. Botha and Cozzens and Ms. Marcus, each of whom is independent under the rules and regulations of the SEC and the listing standards of Nasdaq applicable to audit committee members and each of whom can read and understand fundamental financial statements. During the year ended December 31, 2018 and until his resignation in January 2019, John Steuart served on our board of directors, and also served on the audit committee as its chair. Ms. Marcus currently serves as chair of the audit committee. Our board of directors has determined that Ms. Marcus qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of Nasdaq.

The audit committee of our board of directors oversees our accounting practices, system of internal controls, audit processes and financial reporting processes. Among other things, our audit committee is responsible for reviewing our disclosure controls and processes and the adequacy and

effectiveness of our internal controls. It also discusses the scope and results of the audit with our independent registered public accounting firm, reviews with our management and our independent registered public accounting firm our interim and year-end operating results and, as appropriate, initiates inquiries into aspects of our financial affairs. Our audit committee is responsible for establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters, and for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters. In addition, our audit committee has sole and direct responsibility for the appointment, retention, compensation and oversight of the work of our independent registered public accounting firm, including approving services and fee arrangements. Significant related party transactions will be approved by our audit committee before we enter into them, as required by applicable rules and listing standards.

#### *Compensation Committee*

Our compensation committee was established in October 2013. During the year ended December 31, 2018, our compensation committee held six meetings. The members of our compensation committee are currently Mr. Cozzens and Dr. Healy, each of whom our board of directors has determined qualify as independent under Rule 10C of the Exchange Act and related Nasdaq listing standards, and each of whom is an “outside director” as such term is defined under Section 162(m) of the Internal Revenue Code of 1986, as amended, and a “non-employee director” as such term is defined under Rule 16b-3 of the Exchange Act. Mr. Cozzens serves as chair of the compensation committee. During the year ended 2018 and until his resignation in January 2019, Mr. Steuart served as a member of the compensation committee. The purpose of our compensation committee is to discharge the responsibilities of our board of directors relating to compensation policies and programs. Among other things, specific responsibilities of our compensation committee include evaluating the performance of our chief executive officer and determining our chief executive officer’s compensation. The compensation committee also determines the compensation of our other executive officers in consultation with our chief executive officer. In addition, our compensation committee administers our stock-based compensation plans, including granting equity awards and approving modifications of such awards. Our compensation committee also reviews and approves various other compensation policies and matters.

During the year ended December 31, 2018, our compensation committee engaged the services of Radford, a compensation consulting firm, to advise the compensation committee regarding the amount and types of compensation that we provide to our executive and senior officers and directors and how our compensation practices compared to the compensation practices of other companies. Radford reports directly to the compensation committee. Radford does not provide any services to us other than the services provided to the compensation committee. The compensation committee believes that Radford does not have any conflicts of interest in advising the compensation committee under applicable SEC rules or Nasdaq listing standard.

Our executive officers may make recommendations on the form and amount of executive compensation, but the compensation committee makes the final decision and is not bound by executive officer recommendations. Our compensation committee has delegated authority to a committee of executive officers to grant options and restricted stock units to employees who (i) are not “officers” under Rule 16a-1(f) under the Exchange Act or (ii) do not report directly to our chief executive officer.

#### *Nominating and Corporate Governance Committee*

Our nominating and corporate governance committee was established in May 2015. During the year ended December 31, 2018, our nominating and corporate governance committee held three meetings. The members of our nominating and corporate governance committee are Mr. Botha, Drs. Driscoll and Healy, and Ms. Marcus, each of whom is independent under the rules and regulations of

the SEC and Nasdaq. Ms. Marcus serves as chair of the nominating and corporate governance committee. Dr. Driscoll's service on the nominating and corporate governance committee will end when his term expires at the Annual Meeting. The nominating and corporate governance committee oversees the nomination of directors, including, among other things, identifying, evaluating and making recommendations of nominees to our board of directors and evaluates the performance of our board of directors and individual directors. Our nominating and corporate governance committee is also responsible for reviewing developments in corporate governance practices, evaluating the adequacy of our governance practices and making recommendations to our board of directors concerning corporate governance matters.

When considering potential candidates for membership on our board of directors, our nominating and corporate governance committee considers relevant business and other experience and demonstrated character and judgment as described in our Policies and Procedures for Director Candidates, which are posted in the Investor Relations section of our website at <http://investor.natera.com>. There are no differences in the manner in which our nominating and corporate governance committee evaluates a candidate that is recommended for nomination for membership on our board of directors by a stockholder, as opposed to a candidate that is recommended for nomination for membership on the board of directors by our nominating and corporate governance committee and our board of directors.

In addition to the considerations described above, our nominating and corporate governance committee considers the current composition of the board of directors in its evaluation of candidates for membership. The board of directors believes that factors such as range and diversity of expertise, perspective in areas relevant to our business, character, judgment, diversity, age, independence, expertise, experience, length of service and other commitments as it relates to each individual board member as well as the board of directors as a whole are important considerations in determining board composition. The nominating and corporate governance committee believes that, as a group, the nominees for election at the Annual Meeting complement the overall composition of our board of directors and bring a diverse range of backgrounds, experiences and perspectives to the board of directors' deliberations.

The nominating and corporate governance committee will consider stockholder nominations for directors submitted in accordance with the procedure set forth in our bylaws and Policies and our Procedures for Director Candidates, which are each posted in the Investor Relations section of our website at <http://investor.natera.com>, as further described below under "Corporate Governance—Stockholder Recommendations for Nominations to the Board of Directors." Our nominating and corporate governance committee has not received any recommended nominations from any of our stockholders in connection with the 2019 Annual Meeting.

Roy Baynes was recommended as a candidate for our board of directors as a result of an introduction by a Natera employee. Gail Marcus was recommended as a candidate for our board of directors as a result of efforts of a third-party search firm.

### **Stockholder Recommendations for Nominations to the Board of Directors**

Our nominating and corporate governance committee has adopted Policies and Procedures for Director Candidates. Stockholder recommendations for candidates to our board of directors must be received by December 31st of the year prior to the year in which the recommended candidates will be considered for nomination, must be directed in writing to Natera, Inc., 201 Industrial Road, Suite 410, San Carlos, CA 94070, Attention: Corporate Secretary, and must include the candidate's name, home and business contact information, detailed biographical data and qualifications, information regarding any relationships between us and the candidate within the last three years and evidence of the recommending person's ownership of our capital stock. Such recommendations must also include a

statement from the recommending stockholder in support of the candidate, particularly within the context of the criteria for membership on the board of directors, including issues of character, judgment, diversity, age, independence, expertise, corporate experience, other commitments and the like, personal references and an indication of the candidate's willingness to serve.

### **Compensation Committee Interlocks and Insider Participation**

As noted above, during the year ended December 31, 2018, the compensation committee of our board of directors was comprised of Messrs. Cozzens and Steuart and Dr. Healy. Following Mr. Steuart's resignation from our board in January 2019, the compensation committee is currently comprised of Mr. Cozzens and Dr. Healy. None of our executive officers serves, or served during our year ended December 31, 2018, as a member of the board of directors or compensation committee of any other entity that has or has had one or more executive officers serving as a member of our board of directors or our compensation committee.

### **Meetings of the Board of Directors**

The full board of directors met eight times during the year ended December 31, 2018. No director attended fewer than 75% of the total number of meetings of the board of directors and of any committees of the board of directors of which he or she was a member during the year ended December 31, 2018.

It is our policy that directors are invited and encouraged to attend our annual meetings of stockholders. We have scheduled our Annual Meeting on the same day as a regularly scheduled board of directors meeting in order to facilitate attendance by the members of our board of directors. Five of our directors attended our annual meeting of stockholders in 2018.

### **Board Oversight of Risk**

One of the key functions of our board of directors is informed oversight of our risk management process. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure. Our executive and senior officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its oversight function directly as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. For example, our audit committee is responsible for overseeing the management of risks associated with our financial reporting, accounting and auditing matters; our compensation committee oversees the management of risks associated with our compensation policies and programs; and our nominating and corporate governance committee oversees the management of risks associated with director independence, conflicts of interest, composition and organization of our board of directors and director succession planning.

### **Director Compensation**

Our board of directors approves the form and amount of director compensation. Our compensation committee and executive officers may make recommendations on the form and amount of director compensation, but the board makes the final decision and is not bound by compensation committee or executive officer recommendations.

Under our non-employee director compensation program, as amended in August 2015, during the year ended December 31, 2018, non-employee directors received an annual stock option grant of 11,169 shares to be granted on or as soon as reasonably practicable following our annual meeting of stockholders. Each such option vests in full following the completion of 12 months of continuous service as a member of our board of directors following the grant date, provided that such option will become fully vested on the date of our next annual stockholder meeting following the date of grant if



such date is less than 12 months from the grant date. In addition, new non-employee directors receive an initial stock option grant of 16,530 shares, to be granted on or as soon as reasonably practicable following the date of such director's initial election to our board of directors. Such option vests in equal annual installments over three years of continuous service following the director's election to our board of directors. Further, each option held by a non-employee director will become fully vested if we are subject to a change in control prior to the termination of a director's service.

In addition, during the year ended December 31, 2018 each non-employee director was eligible to receive compensation for his or her service on our board of directors and committees thereof consisting of annual cash retainers as follows.

<u>Position</u>	<u>Retainer (\$)</u>
Board Member . . . . .	35,000
Lead Independent Director . . . . .	15,000
Audit Committee Chair . . . . .	15,000
Compensation Committee Chair . . . . .	12,000
Nominating and Corporate Governance Committee Chair . . . . .	10,000
Audit Committee Member . . . . .	7,500
Compensation Committee Member . . . . .	6,000
Nominating and Corporate Governance Committee Member . . . . .	5,000

In March 2019, upon the recommendation of the compensation committee, our board of directors approved increases to our director compensation to more closely align with compensation programs of other companies in our peer group, as well as our compensation philosophy. Effective March 2019, new non-employee directors are eligible to receive an initial stock option grant of 33,000 shares, to be granted on or as soon as reasonably practicable following the date of such director's initial election to our board of directors, and each continuing non-employee director is eligible to receive an annual stock option grant of 22,000 shares, to be granted on or as soon as reasonably practicable following the date of our annual stockholder meeting. The vesting and other terms for each type of grant, described above, remain unchanged. In addition, each non-employee director is eligible to receive compensation for his or her service on our board of directors and committees thereof consisting of annual cash retainers as follows. All other compensation terms remain unchanged.

<u>Position</u>	<u>Retainer (\$)</u>
Board Member . . . . .	40,000
Lead Independent Director . . . . .	20,000
Audit Committee Chair . . . . .	20,000
Compensation Committee Chair . . . . .	15,000
Nominating and Corporate Governance Committee Chair . . . . .	10,000
Audit Committee Member . . . . .	10,000
Compensation Committee Member . . . . .	7,500
Nominating and Corporate Governance Committee Member . . . . .	5,000
Audit Committee Observer . . . . .	7,500

Under our director compensation program, as amended, each non-employee director may elect to receive all or a portion of his or her annual cash retainer(s) in the form of fully vested options to purchase shares of our common stock. Such options are granted by our compensation committee on a quarterly basis, in arrears, with an aggregate grant date fair value equal to the elected cash amount that otherwise would have been payable for such quarter, with the number of shares subject to such options computed in accordance with the Black-Scholes model used by us for valuing options in our financial statements. Each such option has a term of ten years (subject to earlier expiration upon the



termination of the director's service) and is granted with an exercise price equal to the closing price per share of our common stock on the grant date.

Although we have a practice of granting options to our non-employee directors as soon as practicable following the date of our annual meeting, we did not make such option grants for our 2018 fiscal year until September 2018. To compensate our non-employee directors for the appreciation in value of our common stock between the date of our annual meeting and the grant date of such options, in 2019 our board of directors is expected to approve a special one-time grant of restricted stock units for our non-employee directors.

In connection with his resignation as a member of our board of directors in January 2019, Mr. Steuart signed a consulting agreement with us pursuant to which he will consult with and advise Natera from time to time, as requested by the company. In consideration for his consulting services, Mr. Steuart was granted an extended right of exercise on all of his options outstanding as of the date of his consulting agreement, from three months after termination of services under such agreement to two years after such termination of services.

We have a policy of reimbursing our directors for their reasonable out-of-pocket expenses incurred in attending board of directors and committee meetings.

The following table sets forth information about the compensation for service during the year ended December 31, 2018 of the non-employee members of our board of directors who served as a director during such year. A non-employee director is a director who is not employed by us and who does not receive compensation from us or have a business relationship with us that would require disclosure under certain SEC rules. Other than as set forth in the table and described more fully below, we did not pay any fees to, make any equity awards or non-equity awards to or pay any other compensation to the non-employee members of our board of directors for service during the year ended December 31, 2018. Neither Dr. Rabinowitz, our Chief Executive Officer during the year ended December 31, 2018 and currently serving as our Executive Chairman, nor Mr. Sheena, our Chief Technology Officer, received any compensation from us for service as a director during the year ended December 31, 2018 and are not included in the table below.

<u>Name</u>	<u>Fees Earned or Paid in Cash (\$)<sup>(1)</sup></u>	<u>Option Awards (\$)<sup>(2)(3)(4)(5)</sup></u>	<u>Total (\$)</u>
Roy Baynes*	15,217	240,346	255,563
Roelof F. Botha	—	209,247	209,247
Todd Cozzens	54,500	162,397	216,897
Dr. Edward C. Driscoll, Jr.	40,000	162,397	202,397
Dr. James I. Healy	41,000	162,397	203,397
Gail Marcus	22,500	181,767	204,267
Herm Rosenman	35,000	162,397	197,397
John Steuart	—	204,374	204,374

\* Mr. Baynes was elected to our board of directors effective as of July 25, 2018.

- (1) The amounts shown in this column represent the aggregate amounts of all fees earned or paid in cash for services as a director in 2018 as discussed above.
- (2) The amounts in this column include the aggregate grant date fair value of option awards granted to or earned by the director for compensation for service during the year ended December 31, 2018, computed in accordance with FASB ASC Topic 718. See Note 8 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 15, 2019, for a discussion of the assumptions made by us in determining the grant date fair values of our equity awards.

The amounts in this column consist of:

- (i) \$15,621 with respect to the option granted to Mr. Botha on April 13, 2018, \$15,616 with respect to the option granted to Mr. Botha on July 13, 2018, \$15,613 with respect to the option granted to Mr. Botha on October 26, 2018, and \$15,625 with respect to the option granted to Mr. Botha on January 25, 2019;
  - (ii) \$162,397 with respect to the options granted to each of Messrs. Botha, Cozzens, Rosenman and Steuart, Drs. Driscoll and Healy, and Ms. Marcus on September 14, 2018;
  - (iii) \$240,326 with respect to the option granted to Mr. Baynes on September 14, 2018;
  - (iv) \$5,621 with respect to the option granted to Ms. Marcus on April 13, 2018, \$5,619 with respect to the option granted to Ms. Marcus on July 13, 2018, \$5,621 with respect to the option granted to Ms. Marcus on October 26, 2018, and \$5,618 with respect to the option granted to Ms. Marcus on January 25, 2019; and
  - (v) \$13,995 with respect to the option granted to Mr. Steuart on April 13, 2018, \$13,990 with respect to the option granted to Mr. Steuart on July 13, 2018, \$13,992 with respect to the option granted to Mr. Steuart on October 26, 2018, and \$13,997 with respect to the option granted to Mr. Steuart on January 25, 2019.
- (3) The following table summarizes the fully-vested options granted to our non-employee directors in lieu of cash retainers for our fiscal year 2018:

	Grant Date	Exercise Price (\$)	Option Awards		
			R. Botha	G. Marcus	J. Steuart
Q1 . . . . .	4/13/2018	10.29	2,565	923	2,298
Q2 . . . . .	7/13/2018	21.59	1,220	439	1,093
Q3 . . . . .	10/26/2018	20.27	1,300	468	1,165
Q4 . . . . .	1/25/2019	7.89	1,980	712	1,774

On April 13, 2018, Ms. Marcus was also granted an option to purchase 412 shares of our common stock in lieu of her cash retainer earned for services during the fourth quarter of 2017, at an exercise price of \$10.29 per share.

- (4) On September 14, 2018, Mr. Baynes was granted an initial option as a non-employee director to purchase 16,530 shares of our common stock, and each of Messrs. Botha, Cozzens, Rosenman and Steuart, Drs. Driscoll and Healy, and Ms. Marcus were each granted an annual option as a non-employee director to purchase 11,169 shares of our common stock. Each such option was granted with an exercise price of \$24.42 per share.
- (5) Amounts in this column may not equal the sum of the amounts described under Footnote 3 above due to rounding.

As of December 31, 2018, Mr. Baynes held outstanding options to purchase 16,530 shares of our common stock; Mr. Botha held outstanding options to purchase 62,103 shares of our common stock; Mr. Cozzens held outstanding options to purchase 114,365 shares of our common stock; Dr. Driscoll held outstanding options to purchase 41,931 shares of our common stock; Dr. Healy held outstanding options to purchase 33,507 shares of our common stock; Ms. Marcus held outstanding options to purchase 31,825 shares of our common stock; Mr. Rosenman held outstanding options to purchase 166,103 shares of our common stock; and Mr. Steuart held outstanding options to purchase 59,128 shares of our common stock.

**Stockholder Communications with the Board of Directors**

Stockholders wishing to communicate with the board of directors or with an individual member of the board of directors may do so by writing to the board of directors or to the particular member of the board of directors, care of the Corporate Secretary by mail to our principal executive offices, Attention: Corporate Secretary. The envelope should indicate that it contains a stockholder communication. All such stockholder communications will be forwarded to the director or directors to whom the communications are addressed.

## EXECUTIVE OFFICERS

The following table provides information concerning our executive officers as of March 30, 2019:

<u>Name</u>	<u>Age</u>	<u>Position(s)</u>
Matthew Rabinowitz . . . . .	46	Executive Chairman
Steve Chapman . . . . .	40	Chief Executive Officer, President and Director
Jonathan Sheena . . . . .	46	Chief Technology Officer and Director
Michael Brophy . . . . .	39	Chief Financial Officer
Robert Schueren . . . . .	57	Chief Operating Officer

*Matthew Rabinowitz.* Effective January 2, 2019, Dr. Matthew Rabinowitz resigned as our Chief Executive Officer and became our Executive Chairman. See biographical information set forth above under “Proposal One—Election of Directors—Information Regarding the Nominees and Other Directors.”

*Steve Chapman.* Effective January 2, 2019, Mr. Chapman succeeded Dr. Matthew Rabinowitz as our Chief Executive Officer. See biographical information set forth above under “Proposal One—Election of Directors—Information Regarding the Nominees and Other Directors.”

*Jonathan Sheena.* See biographical information set forth above under “Proposal One—Election of Directors—Information Regarding the Nominees and Other Directors.”

*Michael Brophy* has served as our Chief Financial Officer since February 2017. Previously, he served as our Senior Vice President, Finance and Investor Relations since September 2016, and prior to that, as our Vice President, Corporate Development and Investor Relations since September 2015. Prior to joining Natera, Mr. Brophy served as an executive director from January 2014 to September 2015, and as a vice president from 2011 to 2013, in the investment banking division at Morgan Stanley where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds an M.B.A. from the University of California, Los Angeles and a Bachelor of Science in Economics from the United States Air Force Academy.

*Robert Schueren* has served as our Chief Operating Officer since January 2019. Prior to joining Natera, Mr. Schueren served as chief executive officer and president of IntegenX Inc., a biotechnology company, from March 2013 to January 2019. Mr. Schueren served as vice president and general manager of the Genomics Solutions division at Agilent Technologies Inc. from January 2010 to January 2013; and prior to that, Mr. Schueren served at various companies including Genentech, Inc. and Arcturus Bioscience. Mr. Schueren holds a Bachelor of Science in Pharmacy from Temple University.

## EXECUTIVE COMPENSATION

### Summary Compensation Table

The following table provides information concerning the compensation for services rendered during the years ended December 31, 2017 and 2018 by our Chief Executive Officer and our two other most highly compensated executive officers as of December 31, 2018, whom we refer to as our named executive officers.

Name and Principal Position	Year	Salary (\$)	Bonus (\$) <sup>(1)</sup>	Stock Awards (\$) <sup>(2)</sup>	Option Awards (\$) <sup>(2)</sup>	Non-Equity Incentive Plan Compensation (\$) <sup>(3)</sup>	Total (\$)
Matthew Rabinowitz . . . Chief Executive Officer, President, and Chairman	2018	500,000	110,511	469,410 <sup>(4)</sup>	4,074,476 <sup>(5)</sup>	213,110	5,367,507
	2017	505,443	—	—	2,422,500	76,989	2,292,432
Michael Brophy . . . . . Chief Financial Officer	2018	340,000	52,515	449,014 <sup>(6)</sup>	188,015 <sup>(7)</sup>	136,469	1,166,013
	2017	329,848	—	186,079	611,325	66,285	1,193,537
Steve Chapman . . . . . Chief Operating Officer	2018	372,927	32,089	341,315 <sup>(8)</sup>	569,963 <sup>(9)</sup>	166,861	1,483,155
	2017	368,616	—	186,079	908,325	164,218	1,627,238

- (1) Represents amounts paid in March 2018 representing a special retention bonus paid to all employees who were eligible to receive incentive compensation, in recognition of performance and contributions to the success of the business, which such bonus is repayable in full to the Company if such executive is involuntarily terminated for cause or resigns employment for any reason prior to 12 months from March 12, 2018.
- (2) Represents the aggregate grant date fair value of equity awards granted to the officer in the applicable fiscal year, computed in accordance with FASB ASC Topic 718. See Note 8 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 15, 2019 for a discussion of the assumptions made by us in determining the grant date fair value of our equity awards.
- (3) Represents amounts paid in March 2019 for service during the year ended December 31, 2018 pursuant to the Company's Management Cash Incentive Plan.
- (4) Represents restricted stock units covering (i) 45,090 shares of our common stock granted on March 9, 2018 with an aggregate grant date fair value of \$418,886, and (ii) 4,910 shares of our common stock granted on April 13, 2018 with an aggregate grant date fair value of \$50,524, in each case vesting over four years of continuous service provided by the executive following the grant date, with 25% vesting upon completion of 12 months of service and the remainder in 12 substantially equal quarterly installments thereafter.
- (5) Represents the sum of (i) \$699,500, the aggregate grant date fair value of an option to purchase 179,820 shares of our common stock granted on March 9, 2018, which vests over four years of continuous service following March 9, 2018, with 25% vesting upon completion of 12 months of service and the remainder in 36 substantially equal monthly installments thereafter; (ii) \$86,976, the aggregate grant date fair value of an option to purchase 20,180 shares of our common stock granted on April 13, 2018, which vests four years of continuous service following April 13, 2018, with 25% vesting upon completion of 12 months of service and the remainder in 36 substantially equal monthly installments thereafter; and \$3,288,000, the aggregate grant date fair value of a milestone-based option to purchase 600,000 shares of our common stock granted on December 28, 2018, which fully vests following achievement of the relevant milestone. With respect to the milestone-based option, the grant date fair value is based on the probable outcome of the condition as of such grant date. The maximum grant date fair value of such award, assuming the milestone had been achieved, was \$3,288,000.

- (6) Represents a restricted stock unit covering 48,333 shares of our common stock granted on March 9, 2018. Such award vests over four years of continuous service provided by the executive following the grant date, with 25% vesting upon completion of 12 months of service and the remainder in 12 substantially equal quarterly installments thereafter.
- (7) Represents an option to purchase 48,333 shares of our common stock granted on March 9, 2018, which vests over four years of continuous service following March 9, 2018, with 25% vesting upon completion of 12 months of service and the remainder in 36 substantially equal monthly installments thereafter.
- (8) Represents a restricted stock unit covering 36,740 shares of our common stock granted on March 9, 2018. Such award vests over four years of continuous service provided by the executive following the grant date, with 25% vesting upon completion of 12 months of service and the remainder in 12 substantially equal quarterly installments thereafter.
- (9) Represents an option to purchase 146,520 shares of our common stock granted on March 9, 2018, which vests over four years of continuous service following March 9, 2018, with 25% vesting upon completion of 12 months of service and the remainder in 36 substantially equal monthly installments thereafter.

### **Narrative Explanation of Compensation Arrangements with Our Named Executive Officers**

The compensation paid to our named executive officers for the fiscal year ended December 31, 2018 consisted of (i) base salary, (ii) performance-based incentive compensation under our Management Cash Incentive Plan and retention cash bonuses, and (iii) long-term incentive compensation and performance-based compensation in the form of stock options and restricted stock units (RSUs).

The base salaries of all of our executive officers are reviewed from time to time and adjusted when our compensation committee or board of directors determines an adjustment is appropriate.

Dr. Rabinowitz's current base salary is \$333,000, having been decreased in January 2019 upon his resignation from his position as our chief executive officer and president, as described in "*—Certain Developments Following End of Our 2018 Fiscal Year*" below. Prior to his resignation, Dr. Rabinowitz's base salary was \$500,000. He is eligible to earn an annual bonus with a target amount of 50% of his base salary. Although Dr. Rabinowitz spends significant time with us and is active in our management, he has the ability to spend up to one business day per week on other commitments pursuant to his employment agreement.

Mr. Brophy's base salary is \$340,000 and was last increased in March 2018 but with retroactive effect to January 1, 2018. Mr. Brophy is eligible to earn an annual bonus with a target amount of 45% of his annual base salary.

Mr. Chapman's current base salary is \$450,000, having been increased in January 2019 upon his appointment as our Chief Executive Officer and President, as described in "*—Certain Developments Following End of Our 2018 Fiscal Year*" below. Prior to this appointment, Mr. Chapman's salary was \$375,010 and was last increased effective June 2018. Mr. Chapman is eligible to earn an annual bonus with a target amount of 50% of his base salary.

In general, considerations taken into account by us when determining types and amounts of compensation payable to our named executive officers include, but are not limited to (i) overall company performance, (ii) each executive's level and scope of responsibility, (iii) compensation paid to similarly situated executives of companies with which we compete for executive talent and (iv) the vesting schedule and value of previously granted awards.

Pursuant to their amended letter agreements with us, our named executive officers are eligible to receive certain benefits in the event of our change in control or if their employment is terminated under certain circumstances, as described in the footnotes to the "Outstanding Equity Awards at 2018 Fiscal Year-End" table and under "Severance and Change in Control Benefits" below.

### *Certain Developments Following End of Our 2018 Fiscal Year*

In January 2019, Dr. Rabinowitz resigned from his position as our Chief Executive Officer and President, and our board of directors appointed Mr. Chapman as to such roles, in each case with the base salary and annual bonus with the target amounts described above.

In March 2019, as part of its annual review of executive compensation, our compensation committee granted equity awards to our executive officers, including our named executive officers. Mr. Brophy was granted an option to purchase 50,000 shares of our common stock and 17,236 restricted stock units. In addition, Dr. Rabinowitz is eligible to receive an option to purchase 220,000 shares of our common stock, and Mr. Chapman is eligible to receive an option to purchase 100,000 shares of our common stock and 50,000 restricted stock units. In granting such awards, our compensation committee and our board considers data and recommendations provided by Radford, our compensation committee's compensation consultant, as well as the recommendation made by Mr. Chapman with respect to his team.

All of the granted awards described above vest over four years of continuous service, with 25% vesting after the completion of one year of service and the remainder vesting in installments over an additional three years of service. Such awards are subject to the same acceleration provisions as are described below under "Severance and Change in Control Benefits."

### *Employee Benefits and Perquisites*

Our named executive officers are eligible to participate in our health and welfare plans to the same extent as are all full-time employees generally. We generally do not provide our named executive officers with perquisites or other personal benefits.

### *Retirement Benefits*

We have established a 401(k) tax-deferred savings plan, which permits participants, including our named executive officers, to make contributions by salary deduction pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended. We are responsible for administrative costs of the 401(k) plan. Effective April 2016, we have elected to match contributions made by our employees, including our named executive officers, to the 401(k) plan. We match the employee's contributions to the 401(k) plan in an amount equal to 50% of the employee's contribution, up to 6% of the employee's compensation (comprising base salary and bonus) and subject to other limitations under applicable laws. For all employees hired on or after January 1, 2015, matching contributions vest 25% after the first full year of service, 50% after the second full year of service, 75% after the third full year of service, and 100% after the fourth full year of service. Matching contributions are fully vested for all employees hired before January 1, 2015, including all of our named executive officers except for Mr. Brophy, who was hired in September 2015.

### *Equity Compensation*

We offer stock options and stock unit awards to our named executive officers as the long-term incentive component of our compensation program. We typically grant equity awards to new hires upon their commencing employment with us. Stock options allow employees to purchase shares of our common stock at a price per share equal to the fair market value of our common stock on the date of grant and may or may not be intended to qualify as "incentive stock options" for U.S. federal income tax purposes. Stock units provide full value awards to our employees upon vesting of such awards without requiring the recipient to pay an exercise price or purchase price for such awards. Historically, and most typically, our equity awards vest over four years, subject to the employee's continued employment with us on each vesting date. However, from time to time, we have granted equity awards



with different vesting schedules, including both stock options and stock unit awards with performance-based vesting terms.

In 2018, we granted equity awards to our named executive officers as described in the “Outstanding Equity Awards at Fiscal 2018 Year-End” table below, as well as to a significant number of our other employees.

As described in the footnotes to the “Outstanding Equity Awards at 2018 Fiscal Year-End” table and under “Severance and Change in Control Benefits,” equity awards granted to our named executive officers are subject to accelerated vesting in the event such officer is subject to an involuntary termination or if we experience a change in control. In the event of a conflict or inconsistency between the terms of any agreements providing for acceleration of our officers’ equity awards, such officer will be entitled to whichever provision provides the greatest benefit.

**Outstanding Equity Awards at 2018 Fiscal Year-End**

The following table provides information regarding each unexercised option and all unvested stock held by each of our named executive officers as of December 31, 2018. The number of shares subject to each award and, where applicable, the exercise price per share, reflect all changes as a result of our capitalization adjustments.

The vesting schedule applicable to each outstanding award is described in the footnotes to the table below.

Name	Option Awards						Stock Awards	
	Vesting Commencement Date	Equity Incentive Plan Awards: Securities Underlying Unearned, Unexercised Options (#)	Number of Securities Underlying Unexercised Options (#) Vested	Number of Securities Underlying Unexercised Options (#) Unvested	Option Exercise Price (\$)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested <sup>(1)</sup> (\$)
Matthew Rabinowitz . . . . .	5/19/2011		341,032 <sup>(2)</sup>	0	0.5542	5/18/2021		
	9/1/2012		324,205 <sup>(3)</sup>	0	1.1410	9/19/2022		
	2/25/2014		630,036 <sup>(4)</sup>	0	2.6569	2/24/2024		
	11/20/2014		495,704 <sup>(5)</sup>	117,792	5.3953	12/9/2024		
	4/1/2016		200,000 <sup>(6)</sup>	100,000	9.59	4/7/2026		
	6/9/2017		84,375 <sup>(6)</sup>	140,625	10.41	6/8/2027		
		125,000 <sup>(7)</sup>	56,250	18,750	10.41	6/8/2027		
	3/9/2018		0 <sup>(6)</sup>	179,820	9.29	3/8/2028		
	3/9/2018						45,090 <sup>(8)</sup>	629,456
	4/13/2018		0 <sup>(6)</sup>	20,180	10.29	4/12/2028		
	4/13/2018						4,910 <sup>(8)</sup>	68,544
	12/28/2018	600,000 <sup>(9)</sup>			13.04	12/27/2028		
Michael Brophy . . . . .	9/4/2015		78,750 <sup>(6)</sup>	11,250	9.48	10/8/2025		
	4/1/2016		20,000 <sup>(6)</sup>	10,000	9.59	4/7/2026		
	3/21/2017		46,921 <sup>(6)</sup>	60,329	10.41	6/8/2027		
	3/21/2017						10,056 <sup>(8)</sup>	140,382
	3/9/2018		0 <sup>(6)</sup>	48,333	9.29	3/8/2028		
	3/9/2018						48,333 <sup>(8)</sup>	674,729
Steve Chapman . . . . .	2/16/2015		44,094 <sup>(6)(10)</sup>	1,918	7.45	3/25/2025		
	4/1/2016		46,666 <sup>(6)(10)</sup>	23,334	9.59	4/7/2026		
	3/21/2017		46,921 <sup>(6)(10)</sup>	60,329	10.41	6/8/2027		
	3/21/2017						10,056 <sup>(8)</sup>	140,382
	3/12/2017		21,875 <sup>(6)</sup>	28,125	10.73	7/13/2027		
	3/9/2018		0 <sup>(6)</sup>	146,520	9.29	3/8/2028		
	3/9/2018						36,740 <sup>(8)</sup>	512,890

- (1) Market value is based on the fair market value of our common stock on December 31, 2018, the last trading day of fiscal year 2018, which was \$13.96.
- (2) Option vested over four years of continuous service following the vesting commencement date set forth above.
- (3) Option fully vested on an accelerated basis upon the completion of our initial public offering.
- (4) Option was fully vested as of the date of grant.
- (5) Option vested over five years of continuous service following the vesting commencement date set forth above, with 40% vesting on November 19, 2016, and the remainder in 36 substantially equal monthly installments thereafter. On January 3, 2017, this option was modified pursuant to an action of our compensation committee such that 60% vested on November 19, 2017, and the remainder in 24 substantially equal monthly installments thereafter.
- (6) Option vests over four years of continuous service following the vesting commencement date set forth above, with 25% vesting upon completion of 12 months of service and the remainder in 36 substantially equal monthly installments thereafter.
- (7) Represents a performance-based option to purchase 200,000 shares of our common stock, which vests in substantially equal quarterly installments following achievement of certain specified milestones, contingent on continuous service through each such vesting date. On April 11, 2018, our compensation committee confirmed



achievement of one such milestone, which triggered vesting of 75,000 of the option shares beginning on such date. On March 21, 2019, our compensation committee confirmed achievement of another of such milestones, which triggered vesting of 50,000 of the option shares beginning on such date.

- (8) Restricted stock units vest over four years of continuous service following the vesting commencement date set forth above, with 25% vesting upon completion of 12 months of service and the remainder in 12 substantially equal quarterly installments thereafter.
- (9) Represents a performance-based option to purchase 600,000 shares of our common stock, which fully vests upon achievement of a specified milestone, contingent on continuous service through such vesting date.
- (10) 25% of the option will vest if we are subject to a change in control, and an additional 25% of the option will vest if Mr. Chapman is subject to an involuntary termination within 12 months of such change in control.

### **Severance and Change in Control Benefits**

Pursuant to our arrangements with each of Dr. Rabinowitz and Messrs. Brophy and Chapman, as modified by our compensation committee in August 2017, if we terminate the employment of such executive for reasons other than good cause (including such executive's death or permanent disability), or if such executive resigns for certain good reasons, but only if such termination occurs on or after the date that he has completed three years of continuous service with the Company, then he will be eligible to receive:

With respect to Dr. Rabinowitz:

- a lump-sum cash payment equal to nine months' base salary, except that such lump-sum cash payment will be equal to 18 months' base salary if such termination is within 12 months following a change in control of the Company;
- payment by us of the monthly premiums under COBRA for up to 12 months, except that such monthly premiums will continue for up to 18 months if such termination is within 12 months following a change in control of the Company; and
- accelerated vesting of equity or equity-based awards equal to the greater of (i) 50% of his then-unvested equity or equity-based awards and (ii) forward vesting of such equity or equity-based awards as if he had provided an additional 12 months of service to us, except that if such termination is within 12 months following a change in control of the Company and such termination is other than due to cause or permanent disability, or if he resigns due to a reduction in his base salary or following notice that his principal workplace will be relocated by more than 30 miles, Dr. Rabinowitz will receive accelerated vesting with respect to 100% of his then-unvested equity or equity-based awards.

With respect to Mr. Brophy:

- a lump-sum cash payment equal to six months' base salary, except that such lump-sum cash payment will be equal to 12 months' base salary if such termination is within 12 months following a change in control of the Company;
- payment by us of the monthly premiums under COBRA for up to 12 months; and
- accelerated vesting of equity or equity-based awards equal to the greater of (i) 50% of his then-unvested equity or equity-based awards and (ii) forward vesting of such equity or equity-based awards as if he had provided an additional 12 months of service to us, except that if such termination is within 12 months following a change in control of the Company and such termination is not an involuntary termination resulting solely from a reduction of Mr. Brophy's level of authority or responsibility, Mr. Brophy will receive accelerated vesting with respect to 100% of his then-unvested equity or equity-based awards.

With respect to Mr. Chapman:

- a lump-sum cash payment equal to 12 months' base salary, except that such lump-sum cash payment will be equal to 18 months' base salary, plus incentive compensation calculated as if all performance criteria had been satisfied at 100% of the applicable target level, if such termination is within 18 months following a change in control of the Company;
- payment by us of the monthly premiums under COBRA for up to 12 months, except that such monthly premiums will continue for up to 18 months if such termination is within 12 months following a change in control of the Company; and
- accelerated vesting of equity or equity-based awards equal to the greater of (i) 50% of his then-unvested equity or equity-based awards and (ii) forward vesting of such equity or equity-based awards as if he had provided an additional 12 months of service to us, except that if such termination is within 18 months following a change in control of the Company and such termination is not an involuntary termination resulting solely from a reduction of Mr. Chapman's level of authority or responsibility, Mr. Chapman will receive accelerated vesting with respect to 100% of his then-unvested equity or equity-based awards.

“Good reason” means a resignation after one of the following conditions has come into existence without the officer's consent:

- a reduction in such executive officer's base salary;
- a change in such executive officer's position with us that materially reduces his level of authority or responsibility; or
- a relocation of such executive officer's principal workplace by more than 30 miles.

A “change in control” means the consummation of our merger or consolidation with or into another entity or our dissolution, liquidation or winding up.

In addition, in the event that we are subject to a change in control, 50% of the then-unvested portion of any equity or equity-based awards granted to Dr. Rabinowitz will become fully vested and, if applicable, exercisable, and the remaining unvested portion will vest over the shorter of 12 months or the then-remaining vesting period.

## SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 26, 2019 for:

- each of our named executive officers;
- each of our directors;
- all of our executive officers and directors as a group; and
- each person, or group of affiliated persons, who is known by us to beneficially own 5% or more of our common stock.

We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws.

Applicable percentage ownership is based on 63,127,816 shares of common stock outstanding at March 26, 2019. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options and restricted stock units held by that person or entity that are currently exercisable or that will become exercisable within 60 days of March 26, 2019. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Natera, Inc., 201 Industrial Road, Suite 410, San Carlos, California 94070.

<u>Name of Beneficial Owner</u>	<b>Shares Beneficially Owned</b>	
	<u>Shares</u>	<u>%</u>
<b>Named Executive Officers and Directors:</b>		
Roy Baynes . . . . .	—	*
Roelof F. Botha <sup>(1)</sup> . . . . .	719,124	1.14
Michael Brophy <sup>(2)</sup> . . . . .	60,281	*
Steve Chapman <sup>(3)</sup> . . . . .	98,996	*
Todd Cozzens <sup>(4)</sup> . . . . .	103,196	*
Edward C. Driscoll, Jr. <sup>(5)</sup> . . . . .	75,493	*
James I. Healy <sup>(6)</sup> . . . . .	3,122,898	4.95
Gail Marcus <sup>(7)</sup> . . . . .	15,858	*
Matthew Rabinowitz <sup>(8)</sup> . . . . .	3,544,697	5.47
Herm Rosenman <sup>(9)</sup> . . . . .	190,565	*
Jonathan Sheena <sup>(10)</sup> . . . . .	1,098,218	1.72
All Executive Officers and Directors as a Group (12 persons) . . .	6,145,108	9.29
<b>5% Stockholders:</b>		
Entities affiliated with Sequoia Capital <sup>(11)</sup> . . . . .	7,744,460	12.27
The Vanguard Group, Inc. <sup>(12)</sup> . . . . .	4,274,493	6.77
FMR LLC <sup>(13)</sup> . . . . .	3,908,920	6.19
Prudential Financial, Inc. <sup>(14)</sup> . . . . .	3,797,507	6.02
Jennison Associates LLC <sup>(15)</sup> . . . . .	3,706,873	5.87

\* Represents beneficial ownership of less than 1% of our outstanding common stock.

- (1) Consists of (i) 666,210 shares of common stock held by Mr. Botha and (ii) 52,914 shares of common stock issuable to Mr. Botha pursuant to options exercisable within 60 days of March 26, 2019. Does not include shares held by the Sequoia Capital XII Funds (as defined below); see Footnote (11).

- (2) Consists of (i) 11,075 shares of common stock held by Mr. Brophy and (ii) 49,206 shares of common stock issuable to Mr. Brophy pursuant to options exercisable within 60 days of March 26, 2019.
- (3) Consists of (i) 7,623 shares of common stock held by Mr. Chapman and (ii) 91,373 shares of common stock issuable to Mr. Chapman pursuant to options exercisable within 60 days of March 26, 2019.
- (4) Consists of 103,196 shares of common stock issuable to Mr. Cozzens pursuant to options exercisable within 60 days of March 26, 2019.
- (5) Consists of (i) 44,731 shares of common stock held by Mr. Driscoll and (ii) 75,493 shares of common stock issuable to Dr. Driscoll pursuant to options exercisable within 60 days of March 26, 2019.
- (6) Consists of (i) 22,338 shares of common stock issuable to Dr. Healy pursuant to options exercisable within 60 days of March 26, 2019 and (ii) 3,100,560 shares held by certain entities affiliated with Sofinnova Investments, according to a Schedule 13D/A filed with the SEC on February 12, 2019, by Sofinnova Venture Partners VIII, L.P., which may not be current as of March 26, 2019, over which Dr. Healy may be deemed to have shared voting and dispositive power. The shares held by certain entities affiliated with Sofinnova Investments consists of (i) 1,550,280 shares of common stock held by Sofinnova Venture Partners VIII, L.P. (Sofinnova Venture Partners VIII); and (ii) 1,550,280 shares of common stock held by Sofinnova Venture Partners IX, L.P. (Sofinnova Venture Partners IX, and, collectively, the Sofinnova Funds). Sofinnova Management VIII, L.L.C. (Sofinnova Management VIII) is the general partner of Sofinnova Venture Partners VIII and Anand Mehra, Michael Powell and James I. Healy are the managing members of Sofinnova Management VIII. Sofinnova Venture Partners VIII, Sofinnova Management VIII, Anand Mehra, Michael Powell and James I. Healy may be deemed to have shared voting and dispositive power over the shares owned by Sofinnova Venture Partners VIII. Sofinnova Management IX, L.L.C. (Sofinnova Management IX) is the general partner of Sofinnova Venture Partners IX and Anand Mehra, Michael Powell and James I. Healy are the managing members of Sofinnova Management IX. Sofinnova Venture Partners IX, Sofinnova Management IX, Anand Mehra, Michael Powell and James I. Healy may be deemed to have shared voting and dispositive power over the shares owned by Sofinnova Venture Partners IX. Such entities and individuals expressly disclaim any such beneficial ownership over the shares owned by the Sofinnova Funds, respectively, except to the extent of any pecuniary interest therein, if any. The address of each of the entities identified in this footnote is 3000 Sand Hill Road, Building 4, Suite 250, Menlo Park, California 94025.
- (7) Consists of 15,858 shares of common stock issuable to Ms. Marcus pursuant to options exercisable within 60 days of March 26, 2019.
- (8) Consists of (i) 1,162,556 shares of common stock held by Dr. Rabinowitz, (ii) 613,496 shares of common stock held by the Matthew Rabinowitz Grantor Retained Annuity Trust, and (iii) 1,648,020 shares of common stock issuable to Dr. Rabinowitz pursuant to options exercisable within 60 days of March 26, 2019.
- (9) Consists of (i) 41,141 shares of common stock held by Mr. Rosenman and (ii) 149,424 shares of common stock issuable to Mr. Rosenman pursuant to options exercisable within 60 days of March 26, 2019.
- (10) Consists of (i) 237,770 shares of common stock held by Mr. Sheena and (ii) 860,448 shares of common stock issuable to Mr. Sheena pursuant to options exercisable within 60 days of March 26, 2019.
- (11) According to a Schedule 13G filed with the SEC on February 12, 2016, by Sequoia Capital XII, LP, which may not be current as of March 26, 2019. Does not include shares held by Roelof F. Botha; see Footnote (1). Consists of (i) 6,767,891 shares held by Sequoia Capital XII, LP (Sequoia XII), (ii) 253,240 shares of common stock held by Sequoia Technology Partners XII, LP (Sequoia Technology), and (iii) 723,329 shares held by Sequoia Capital XII Principals Fund LLC (Sequoia Principals). SC XII Management, LLC is the general partner of Sequoia XII and Sequoia Technology and is the managing member of Sequoia Principals (collectively, the Sequoia Capital XII Funds). As a result, and by virtue of the relationships described in this footnote, SC XII

Management, LLC, may be deemed to share beneficial ownership of the shares held by the Sequoia Capital XII Funds. Roelof F. Botha is a managing member of SC XII Management, LLC. The address of each of the entities identified in this footnote is 2800 Sand Hill Road, Suite 101, Menlo Park, California 94025.

- (12) According to a Schedule 13G filed with the SEC on February 11, 2019, by The Vanguard Group, Inc. (Vanguard Group), which may not be current as of March 26, 2019. Vanguard Group has sole voting power with respect to 68,648 shares of common stock and shared voting power with respect to 1,800 shares of common stock; sole dispositive power with respect to 4,207,923 shares of common stock; and shared dispositive power with respect to 66,570 shares of common stock. Includes (i) 64,770 shares held by Vanguard Fiduciary Trust Company, a wholly-owned subsidiary of Vanguard Group and an investment manager of collective trust accounts for Vanguard Group; and (ii) 5,498 shares held by Vanguard Investments Australia, Ltd., a wholly-owned subsidiary of Vanguard Group and an investment manager of Australian investment offerings for Vanguard Group. The address for Vanguard Group. is 100 Vanguard Blvd., Malvern, Pennsylvania 19355.
- (13) According to a Schedule 13G filed with the SEC on February 13, 2019, by FMR LLC, which may not be current as of March 26, 2019. FMR LLC has sole voting power with respect to 293,479 shares of common stock, and sole dispositive power with respect to 3,908,920 shares of common stock. Abigail P. Johnson is a director, the chairman and the chief executive officer of FMR LLC. FMR LLC is a parent holding company. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners representing 49% of the voting power of FMR LLC. As a result, and by virtue of the relationships described in this footnote, FMR LLC and certain of its subsidiaries and affiliates and other companys, may be deemed to share beneficial ownership of the shares held by FMR LLC. The address for FMR LLC is 245 Summer Street, Boston, Massachusetts 02210.
- (14) According to a Schedule 13G filed with the SEC on January 28, 2019, by Prudential Financial, Inc., which may not be current as of March 26, 2019. Consists of (i) 87,884 shares of common stock held by Prudential Retirement Insurance and Annuity Company, (ii) 3,706,873 shares of common stock held by Jennison Associates LLC, and (iii) 2,750 shares of common stock held by Quantitative Management Associates LLC (together with Prudential Retirement Insurance and Annuity Company and Jennison Associates LLC, the Prudential Entities). Prudential Financial, Inc. is a parent holding company and the indirect parent of the Prudential Entities. As a result, and by virtue of the relationships described in this footnote, Prudential Financial, Inc. may be deemed to share beneficial ownership of the shares held by the Prudential Entities. The address for Prudential Financial, Inc. is 751 Broad Street, Newark, New Jersey 07102.
- (15) According to a Schedule 13G filed with the SEC on February 1, 2019. Jennison Associates LLC has sole voting power with respect to 3,706,873 shares of common stock and sole dispositive power with respect to 3,706,873 shares of common stock. Prudential Financial, Inc. indirectly owns 100% of the equity interests described in this footnote and in Footnote (14). As a result, and by virtue of the relationships described in this footnote and Footnote (14), Prudential Financial, Inc. may be deemed to share beneficial ownership of the shares held by Jennison Associates LLC. The address for Jennison Associates LLC is 466 Lexington Avenue, New York, New York 10017.

## EQUITY COMPENSATION PLAN INFORMATION

The following table provides information as of December 31, 2018 with respect to the shares of our common stock that may be issued under our existing equity compensation plans.

<u>Plan Category</u>	<u>Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights</u>	<u>Weighted Average Exercise Price of Outstanding Options, Warrants and Rights<sup>(1)</sup></u>	<u>Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans<sup>(2)</sup></u>
Equity compensation plans approved by stockholders . . . . .	10,547,511	\$7.6863	5,135,636 <sup>(3)</sup>
Equity compensation plans not approved by stockholders . . . . .	—	—	—
Total . . . . .	<u>10,547,511</u>	<u>\$7.6863</u>	<u>5,135,636</u>

- (1) The weighted average exercise price does not take into account outstanding RSUs.
- (2) All of our equity compensation plans have been approved by our stockholders. This information is with respect to the 2007 Stock Plan (the 2007 Plan), the 2015 Equity Incentive Plan (the 2015 Plan) and the 2015 Employee Stock Purchase Plan. The 2015 Plan is the successor to and continuation of the 2007 Plan. As of the effective date of our initial public offering, no additional awards are to be granted under the 2007 Plan, but all stock awards granted under the 2007 Plan remain subject to their existing terms. This column does not reflect 2,482,760 shares that were added to the 2015 Plan and 620,690 shares that were added to the 2015 Employee Stock Purchase Plan on January 2, 2019 pursuant to the stockholder-approved terms of such plans.
- (3) Included in this amount are 2,464,194 shares available for future issuance under our 2015 Employee Stock Purchase Plan and 2,671,442 shares available for future issuance under our 2015 Equity Incentive Plan.

## CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

In addition to the compensation arrangements with our directors and executive officers described elsewhere in this proxy statement, the following is a description of each transaction since January 1, 2018 and each currently proposed transaction in which:

- we have been or are to be a participant;
- the amount involved exceeds or will exceed \$120,000; and
- any of our directors, executive officers or holders of more than 5% of our capital stock, or any immediate family member of or person sharing the household with any of these individuals (other than tenants or employees), had or will have a direct or indirect material interest.

### **Non-binding Memorandum of Understanding with MyOme Inc.**

We have entered into a non-binding memorandum of understanding with MyOme, Inc. for the purpose of collaborating with it on the commercialization of a personal genome report and an enhanced preimplantation diagnostic report. As part of the potential collaboration, we have the non-binding right to receive equity in MyOme, Inc. in certain circumstances. Dr. Rabinowitz, our Executive Chairman, is an executive officer and director and owner of more than 5 percent of MyOme, Inc. Our entry into the non-binding memorandum of understanding was approved by an independent committee of our board of directors.

### **Employment Arrangements with Immediate Family Members of Our Executive Officers and Directors**

Daniel Rabinowitz, a brother of Matthew Rabinowitz, our Executive Chairman of our board of directors, has been employed by us since July 2004. Daniel Rabinowitz serves as our Secretary and General Counsel. During the year ended December 31, 2018, Daniel Rabinowitz received total compensation, including base salary, bonus, equity awards and other compensation, of \$865,524.

Daniel Rabinowitz's compensation level was determined, in part, by reference to similarly situated employees who were not related to an executive officer or director. He was also eligible for equity awards on the same general terms and conditions as applicable to other similarly situated employees who were not related to an executive officer or director.

### **Indemnification Agreements**

We have entered into indemnification agreements with each of our directors and executive officers and certain other key employees. The indemnification agreements provide that we will indemnify each of our directors and executive officers and such other key employees against any and all expenses incurred by that director or executive officer, or other key employee because of his or her status as one of our directors or executive officers, or other key employees, to the fullest extent permitted by Delaware law, our certificate of incorporation and our bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors and executive officers and other key employees in connection with a legal proceeding.

### **Change in Control Arrangements**

Certain of our executive officers have agreements in place that provide for certain benefits in the event of a change in control. For more information regarding these benefits, see "Executive Compensation—Severance and Change in Control Benefits."



## **Policies and Procedures for Related Party Transactions**

We have adopted a formal policy that our executive officers, directors, holders of more than 5% of any class of our voting securities, and any member of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a related party transaction with us without the consent of our audit committee, or other independent members of our board of directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Any request for us to enter into a transaction with an executive officer, director, principal stockholder, or any of their immediate family members or affiliates, in which the amount involved exceeds \$120,000 must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee considers the relevant facts and circumstances available and deemed relevant to our audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related party's interest in the transaction.

### **SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE**

Section 16(a) of the Exchange Act requires that our executive officers and directors and persons who own more than 10% of our common stock, file reports of ownership and changes of ownership with the SEC. Such directors, executive officers and 10% stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

SEC regulations require us to identify in this proxy statement anyone who filed a required report late during the most recent fiscal year. Based on our review of forms we received, or written representations from reporting persons, we believe that during our fiscal year ended December 31, 2018, all Section 16(a) filing requirements were satisfied on a timely basis, other than with respect to certain securities acquired by John Steuart or his affiliates on August 15, 2018, which was then reported on an Annual Statement of Changes in Beneficial Ownership on Form 5 on February 14, 2019.



## AUDIT COMMITTEE REPORT

*The information contained in the following report of Natera's audit committee is not considered to be "soliciting material," "filed" or incorporated by reference in any past or future filing by us under the Securities Exchange Act of 1934 or the Securities Act of 1933 unless and only to the extent that Natera specifically incorporates it by reference.*

### **Role of the Audit Committee**

The audit committee operates under a written charter adopted by our board of directors. The audit committee of our board of directors oversees our accounting practices, system of internal controls, audit processes and financial reporting processes. Among other things, our audit committee is responsible for reviewing our disclosure controls and processes, and the adequacy and effectiveness of our internal controls. It also discusses the scope and results of the audit with our independent registered public accounting firm, reviews with our management and our independent registered public accounting firm our interim and year-end operating results and, as appropriate, initiates inquiries into aspects of our financial affairs. Our audit committee is responsible for establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters, and for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters. In addition, our audit committee has sole and direct responsibility for the appointment, retention, compensation and oversight of the work of our independent registered public accounting firm, including approving services and fee arrangements. Our audit committee will approve significant related party transactions before we enter into them, as required by applicable rules and listing standards. A more detailed description of the functions and responsibilities of the audit committee can be found in Natera's audit committee charter, published under the Governance section of our Investor Relations website at <http://investor.natera.com>.

The audit committee oversees our financial reporting process on behalf of the board of directors. Management is responsible for our internal controls, financial reporting process, selection of accounting principles, determination of estimates and compliance with laws, regulations and ethical business conduct. Our independent registered public accounting firm is responsible for expressing an opinion as to the conformity of our consolidated financial statements with generally accepted accounting principles.

### **Review of Audited Financial Statements for the Year ended December 31, 2018**

The audit committee has reviewed and discussed with Natera's management and Ernst & Young LLP the audited consolidated financial statements of Natera for the year ended December 31, 2018. The audit committee has also discussed with Ernst & Young LLP the matters required to be discussed by applicable requirements of the Public Company Accounting Oversight Board regarding communications between our independent registered public accounting firm and audit committee.

The audit committee has received and reviewed the written disclosures and the letter from Ernst & Young LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant's communications with the audit committee concerning independence, and has discussed with Ernst & Young LLP its independence from us.

Based on the review and discussions referred to above, the audit committee recommended to the board of directors that the audited consolidated financial statements be included in Natera's Annual Report on Form 10-K for the year ended December 31, 2018 for filing with the Securities and Exchange Commission.

### **Submitted by the Audit Committee**

Gail Marcus, Chair  
Roelof F. Botha  
Todd Cozzens

## **OTHER MATTERS**

We know of no other matters to be submitted at the Annual Meeting. If any other matters properly come before the Annual Meeting, it is the intention of the persons named in the proxy card to vote the shares they represent as Natera may recommend.

It is important that your shares be represented at the Annual Meeting, regardless of the number of shares that you hold. You are, therefore, urged to vote at your earliest convenience on the Internet or by telephone as instructed, or by executing and returning a proxy card, if you have requested one, in the envelope provided.

**THE BOARD OF DIRECTORS**

San Carlos, California  
April 4, 2019